Hemispherx Biopharma

Hemispherx Biopharma Inc. (AMEX: HEB) is a biopharmaceutical company based in Orlando, Florida.[1] Founded in 1990, the company has 32 employees.[2]

The company has created an immunomodulatory double stranded RNA drug called Ampligen.[3] The company is developing Ampligen to use as a treatment for chronic fatigue syndrome.[4]

On April 3, 2001, Hemispherx Biopharma, Inc. adjusted and restated its 1999 financial statements to reflect charges relating to an extension of the exercise period to certain warrants as of February 1999.

On April 3, 2006, Hemispherx Biopharma, Inc. restated financial results for 2003 and 2004 due to accounting mistakes related to debentures and warrants issued between March 2003 and August 2005.[5]

In June, 2018, Hemispherx announced that Ampligen had shown effectiveness in activating the TLR3 without triggering T-cell regulatory activities, offering a potentially effective way to treat tumors.[6]

References

  1. ↑ Greenberg, Herb (1998-09-18). "Battle Royale Brewing: Hemispherx Biopharma and Asensio Tangle". TheStreet.com. Archived from the original on 24 August 2009. Retrieved 24 August 2009.
  2. ↑ "Hemispherx Biopharma, Inc". BusinessWeek. Archived from the original on 24 August 2009. Retrieved 24 August 2009.
  3. ↑ "Hemispherx licensed for chemical compound". Philadelphia Business Journal. 2006-08-29. Archived from the original on 24 August 2009. Retrieved 24 August 2009.
  4. ↑ "Hemispherx Biopharma Inc. (use of Ampligen for chronic fatigue syndrome)". Philadelphia Business Journal. 2000-10-06. Retrieved 24 August 2009.
  5. ↑ "Hemispherx delays 2005 statement".
  6. ↑ "Hemispherx Biopharma (HEB) Highlights New Data Showing Ampligen's Positive Role in Reprograming Tumor Microenvironment". Street Insider. 5 June 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.